Daily Download

ISR2.jpg

Injection Site Reactions

Jack Cush, MD
ISRs are common with biologic use
Total%20Biosimilars.Updated.1219.jpg

Even More Biosimilars

Jack Cush, MD
Updated Biosimilars in the US: 11 TNFi and 2 RTX biosimilars
Biosimilars.Updated.1119.jpg

New Biosimilars for Rheumatology - 2019

Jack Cush, MD
4 Slides Reviewing 11 Biosimilars Approved and Indications
ISR.jpg

Biologic Injection Site Reactions

Jack Cush, MD
ISRs Related to IL-1 inhibitors and TNF inhibitors
New.Biosimilars.0719.jpg

anti-TNF Biosimilars in USA

Jack Cush, MD
UPDATED - there are now 9 biosimilar versions of TNF inhibitors
Biosimilar.survey.slides%202017.opener.jpg

Biosimilar Survey Results from Rheumatologists and Patients

Jack Cush, MD

Results from the April 2017 "Live Vote" survey

2017.New_.Biosimilars.jpg

New TNF Inhibitor Biosimilars

Jack Cush, MD
HighRisk.SIE2017.jpg

High Risk for Serious Infection

Jack Cush, MD
Biologic%20patents.jpg

Future Biologic Patent Expirations

Jack Cush, MD
MTX.CVE%20prevention.jpg

DMARDs Under Study for Secondary Prevention of Cardiovascular Events

Jack Cush, MD
Biosimilar%20new%20in2016_0.jpg

3 New TNF Inhibitor Biosimilars Approved in 2016

Jack Cush, MD
Biosimilar%20new%20in2016.jpg (keep)

New Biosimilars 2016: Many Indications Based on Few RCTs

Tammy J. Tilley

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.